# Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

> **NCT01852708** · — · COMPLETED · sponsor: **Natera, Inc.** · enrollment: 1059 (actual)

## Conditions studied

- Trisomy 21
- Trisomy 18
- Trisomy 13
- Sex Chromosome Abnormalities
- Microdeletion Syndromes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01852708
- **Lead sponsor:** Natera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 1059 (ACTUAL)
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852708, "Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01852708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*